Ventilator-associated pneumonia (VAP) is one of the most commonly encountered hospital-acquired
infections in intensive care units and is associated with significant morbidity and high costs of care.
The pathophysiology, epidemiology, treatment and prevention of VAP have been extensively studied for
decades, but a clear prevention strategy has not yet emerged